Forte Biosciences (FBRX) Short-term Investments (2023 - 2026)
Forte Biosciences (FBRX) posted quarterly Short-term Investments of $36.1 million for Q4 2024, up 261.68% quarter-over-quarter from $10.0 million in Q2 2023.
Forte Biosciences (FBRX) Short-term Investments (2023 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Short-term Investments for 2 consecutive years, with $36.1 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Short-term Investments changed N/A year-over-year to $36.1 million; the TTM figure through Dec 2024 stood at $36.1 million (changed N/A YoY), while the FY2024 annual figure was $36.1 million, changed N/A from the prior year.
- Short-term Investments rose to $36.1 million in Q4 2024 per FBRX's latest filing, from $10.0 million in the prior quarter.
- Across five years, Short-term Investments topped out at $36.1 million in Q4 2024 and bottomed at $10.0 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 148.83 Mn |
| Dec 31, 2024 | 36.12 Mn |
| Jun 30, 2023 | 9.99 Mn |